Integrated Drug Discovery, Drug Development and Manufacturing

Request for Services

Dalton Pharma Services is a leading cGMP contract service provider of integrated drug discovery, development and manufacturing services to the pharmaceutical and biotechnology industries. We are FDA Inspected and Health Canada approved, and bring over 30 years of experience to every project. We deliver fully integrated solutions with an emphasis on speed, flexibility and quality. We are experts in Custom Synthesis, cGMP API Manufacturing, Formulation Development, API Process Development, Sterile Filling Services and Accelerated Stability Services.

We understand your project needs and will deliver:

♦   Highest Quality
♦   Shorter Timelines
♦   Minimized Cost
♦   Regulatory Compliance
♦   Keeping you Informed
News
Dalton Pharma Services, a leading North-American contract drug manufacturing organization, today announced that it has been re-certified for a 4th consecutive year as a Great Place to Work® in Canada.
Dalton Pharma Services is proud to announce that our organization has been named on the 2019 list of Best Workplaces™ in Healthcare. Dalton received this honor after a thorough and independent analysis conducted by Great Place to Work®
Dalton`s facility and quality systems used for manufacture and release of APIs were subject to a successful compliant inspection by the US FDA.
Dalton is excited to announce its drug development and manufacturing services agreement with ExCellThera Inc.
As a part of a 10 million dollar facility and capital expansion, Dalton Pharma Services, a leading North American contract research, development & manufacturing organization has invested in a fully automated Sterile Liquid Filling System that will become operational in Q1 of 2019.
Arch Biopartners announces it has engaged Dalton Pharma to perform the good manufacturing practice (GMP) campaign for Metablok, the Company's drug candidate for preventing acute kidney injury.
Dalton expands its elemental analysis testing capabilities with the addition of an ICP-MS System.
Pharmaceutical Outsourcing conducts an interview with Peter Pekos, President & CEO, Dalton Pharma Services.